TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Exercise Training on Gait and Quality of Life in Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of idiopathic Parkinson's disease~* Stage of II or less on Hoehn and Yahr scale~Exclusion Criteria:~* Having musculoskeletal impairments or having excessive pain in any joint that could limit participation in exercise program~* Dementia (MMSE\<24)~* Having balance problems~* Live beyond 45 minutes from Laval University

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Speed TT (Type: EXPERIMENTAL): Walk on treadmill with progressive increases in speed
- Mixed TT (Type: EXPERIMENTAL): Walk on treadmill with progressive increases in speed and incline
- Control (Type: ACTIVE_COMPARATOR): Light-intensity exercise group, work flexibility and coordination

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: An Study of Aripiprazole in the Treatment of Methamphetamine Dependence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients,Diagnostic and Statistical Manual of Mental Disorders 4thed. (DSM-IV) criteria for Methamphetamine dependence.~2. Must sign a Information consent form.~3. Required to provide detailed address and phone number~Exclusion Criteria:~1. Serious organic disease.~2. Suicide ideation or hurt others.~3. Taking antipsychotic within two weeks before.~4. drug allergy to Risperidone or Aripiprazole.~5. pregnancy and breastfeeding women.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Aripiprazole (Type: EXPERIMENTAL): Aripiprazole arm,5mg/pill,10mg/day.last12weeks.
- Sugar pill (Type: PLACEBO_COMPARATOR): placebo arm,5mg/pill,10mg/day,last12weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Colloid Osmotic Pressure and Osmolality in Hyponatremia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients treated for Hyponatremia at the intensive care unit.~Exclusion Criteria:~* Circulatory instable patients in need of treatment for more than the hyponatremia.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hyponatremia (Type: None): Patients treated for hyponatremia (\<125 mmol/L Sodium) in the intensive care department.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With COVID-19 Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Hospitalized within the last 36 hours.~2. Receiving any form of supplementary oxygen therapy at baseline.~3. Confirmed COVID-19 viral infection by RTPCR at screening.~4. Age:~   1. 18-65 years old, OR~  2. \>65 year-olds can be included after Data Monitoring Committee (DMC) approval~Key Exclusion Criteria:~1. Contraindications/hypersensitivity to P histicola or any of the capsule excipients~2. Patients with chronic hypoxia or underlying significant chronic respiratory disease (such as Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Fibrosis, or Bronchiectasis).~3. Admission to ICU at time of screening.~4. Mechanically ventilated, on continuous positive airway pressure (CPAP), or on non-invasive ventilation at the time of screening.~5. Patient is taking a systemic immunosuppressive agent such as, but not limited to, oral steroids, methotrexate, azathioprine, ciclosporin, or tacrolimus, unless these are given as part of COVID standard of care treatment.~6. Patient has a diagnosed primary immunodeficiency.~7. Patient has a diagnosis of HIV/AIDS~8. Patient has pre-existing known chronic kidney disease stage 4 or 5 or requiring renal replacement therapy (i.e. estimated glomerular filtration rate (eGFR) \<30ml/min/1.73m2)~9. Patient has pre-existing known significant liver disease with Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 5.0 x upper limit of normal (ULN)~10. Patient has pre-existing known significant gastrointestinal tract disease expected to affect absorption within the small intestine (e.g. short bowel syndrome, inflammatory bowel disease affecting the small intestine, gastroparesis); or prior malabsorptive bariatric surgery that could interfere with GI delivery and transit time.~11. GI signs or symptoms equivalent to CTCAE v5.0, gastrointestinal disorders, grade 3 or 4 event.~12. Patient has pre-existing known substantially impaired cardiac function or pre-existing clinically significant cardiac diseases, including unstable angina or acute myocardial infarction ≤ 6 weeks prior to Screening.~13. Currently participating in an interventional clinical trial (observational studies allowed).~14. Moribund at time of screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- EDP1815 (Type: EXPERIMENTAL): Patients will receive EDP1815 in addition to standard of care
- Placebo (Type: PLACEBO_COMPARATOR): Patients will receive placebo in addition to standard of care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Four Treatment Modalities in Prostate Cancer With Low or Early Intermediate Risk

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed, biopsy proven adenocarcinoma of the prostate (ultrasound guided biopsy by standardized protocol)~* Men aged 18-75 years~* Recruitment within 3 months after histological confirmation~* Localized prostata cancer \<= cT2a, NX or N0 M0~* PSA \<= 10 ng / ml~* Gleason score \<= 7a (3 +4)~* ECOG performance status 0 or 1~* \<= 30% positive biopsy cores with largest contiguous tumor length \<= 5 mm~* IPSS score \< 18~* Urine flow (Qmax):\> 15 ml / s~Exclusion Criteria:~* Unifocal Gleason 6 cancer \<1mm~* History of treatment for BPH e.g. TURP, HIFU or cryotherapy~* History of radiation therapy to the pelvis~* Life expectancy \<10 years~* ASA \>= 4~* Post-void residual urine \> 50 ml~* Prostate volume on transrectal ultrasound \> 60 cm3~* large median prostate lobe visualized on transrectal ultrasound~* chronic intestinal inflammatory disease covering the rectum~* Other active malignancy within the past 5 years (except for superficial basal cell carcinoma or non muscle infiltrating bladder carcinoma)~* contraindications for prostatectomy, radiation therapy or Active Surveillance~* Patients refusing written informed consent

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- radical prostatectomy (Type: EXPERIMENTAL): Procedure/Surgery: radical prostatectomy
- percutaneous radiation therapy (Type: EXPERIMENTAL): Radiation: percutaneous radiation therapy
- permanent seed implantation (Type: EXPERIMENTAL): Radiation: permanent seed implantation
- Active Surveillance (Type: EXPERIMENTAL): Procedure/Surgery: Active Surveillance

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Adjuvant Radiation Therapy in Treating Patients With Brain Metastases

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of brain metastases from a histologically confirmed primary or metastatic extracranial tumor, meeting 1 of the following criteria:~  * Stable systemic cancer for the last 3 months (achieved by surgery, radiotherapy, chemotherapy, or hormonal therapy), defined as absence of symptomatic or radiological progression~ * Asymptomatic synchronous primary tumor (treatable by surgery, radiotherapy, chemotherapy, or hormonal therapy)~    * No metastases outside the CNS~ * Unknown primary tumor~* Must have one to three brain lesions, confirmed by enhanced MRI prior to radiosurgery or surgery~  * No brain stem metastases~ * No leptomeningeal metastases~ * No brain metastases from small cell lung cancer, lymphoma, leukemia, myeloma, or germ cell tumors~* Patients planning to undergo radiosurgery must meet the following criteria:~  * Largest diameter ≤ 3.5 cm for single metastasis~ * Largest diameter ≤ 2.5 cm for multiple metastases~ * Stereotactic biopsy required if not extracranial tumor (unknown primary tumor) OR extracranial diagnosis made more than 4 years previously~* Prior neurosurgery patients must have undergone complete surgical resection~* No recurrent brain metastases after prior surgery and/or radiosurgery and/or brain radiotherapy~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* WHO 0-2 (may be assessed under steroid therapy)~Life expectancy~* Not specified~Hematopoietic~* Not specified~Hepatic~* Not specified~Renal~* Not specified~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* See Disease Characteristics~* No concurrent chemotherapy during whole brain radiotherapy~Endocrine therapy~* See Disease Characteristics~Radiotherapy~* See Disease Characteristics~Surgery~* See Disease Characteristics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: ImCardia for DHF to Treat Diastolic Heart Failure (DHF) Patient a Pilot Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female able to understand and sign a informed consent~2. Be 50 years of age or older~3. NYHA class III, IV~4. EF \>55%~5. Candidates for aortic valve replacement due to aortic stenosis.~6. Agrees to attend all follow- up evaluations~Exclusion Criteria:~1. Free wall thickness less than11.5mm~2. Adhesions are expected from a previous surgery or medical condition (e.g. s/p chest radiation therapy etc.)~3. Presence of significant myocardial scars (e.g. postinfarction) at proposed site for implant of ImCardia™device Attachment screw.~4. Likely to be need CABG following the implantation of the ImCardia™~5. Intra-cardiac thrombus/mass~6. Myocarditis~7. Acute/chronic pericarditis~8. Not a candidate for sternotomy~9. Active infection~10. Stroke, surgery or ICD within 3 months~11. Acute coronary syndrome during the past 6 months~12. Left ventricular regional wall motion abnormalities~13. Significant valvular disease other that aortic stenosis~14. Significant pulmonary disease~15. A history of alcohol abuse, drug addiction, or other psychosocial condition that would preclude successful participation, or clear judgment and informed consent in the opinion of the Principal Investigator~16. Participating in another trial (other than non-therapeutic or interventional observation) within the last 60 days.~17. History of noncompliance to medical therapy

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ImCardia (Type: EXPERIMENTAL): Aortic Stenosis patients candidates for Aortic Valve Replacement (AVR) implanted with the ImCardia device
- AVR control group (Type: NO_INTERVENTION): Aortic stenosis patients candidates for aortic valve replacement

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: High Dose Oral 4-Aminosalicylic Acid (PASER®) to Control Acute Flares of Mild to Moderate Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-65~* Crohn's disease involving predominantly the ileum and/or cecum. The diagnosis must have been established by radiography, endoscopy and/or biopsy (at least 2 of the 3 modalities) with at least one confirmatory test having been performed no more than 36 months before entry. The diagnosis must have been confirmed by at least one gastroenterologist.~* Harvey Bradshaw Index of at least 7~* The onset of the acute flare should have been abrupt, declaring itself over 72 hours, and should have started no more than 4 weeks before study entry. Symptoms relating to the flare should not have diminished or started to improve prior to entry.~* Written informed consent~Exclusion Criteria:~* Concomitant corticosteroids, including budesonide~* Corticosteroids within the previous 2 months~* Cyclosporine, mycophenolate mofetil or experimental drugs during the last three months~* Maintenance infliximab, or infliximab or other biologics in the preceding 3 months~* Change in dose during previous 4 weeks in 5-aminosalicylate, probiotic and/or antibiotic, or in chronic azathioprine, 6-mercaptopurine, or methotrexate~* If currently using azathioprine, 6-mercaptopurine or methotrexate, these must have been used steadily for at least 4 months~* Current experimental drugs or experimental drugs within the last 3 months~* If the severity of the flare has started to decrease spontaneously~* Coexisting diagnosis of primary sclerosing cholangitis,~* Infectious diarrhea,~* Signs of intestinal obstruction or perforation or abscess,~* New fistulization as part of the acute flare or increased activity in chronic fistula(e) as part of the acute flare,~* Increased activity of pre-existing anal or rectal Crohn's disease as part of the flare~* Allergy or sensitivity to salicylates~* Pregnancy or breast-feeding~* Failure of a woman of child-bearing age to agree to use adequate contraception for the 4 week period of the trial, if sexually active~* Severe renal or hepatic disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Oral granules administered as one 4 g packet three times daily for two weeks followed by one 4 g packet two times daily for two weeks
- P (Type: PLACEBO_COMPARATOR): One packet of oral granules administered three times daily for 2 weeks followed by one packet two times daily for two weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: ICTUS Study: International Citicoline Trial on Acute Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, \>18 years old~* Patients must be treated within 24 hours of their initial stroke symptoms onset.~* Patients with a measurable focal neurological deficit lasting for a minimum of 60 minutes.~* Patients must have a CT scan and/or conventional MRI compatible with the clinical diagnosis of acute ischemic stroke prior to being randomized.~* Patients must have an acute ischemic stroke referable to the middle cerebral artery territory~* At inclusion, NIHSS score \> 7, with at least 2 of these points from sections 5 \& 6 (motor)~* Immediately (i.e. minutes) pre-stroke, MRS \< 2~* Women of childbearing potential must have a negative pregnancy test prior to enrolment~* Signed informed consent~Exclusion Criteria:~* Patients in coma: patients having a score of 2 or higher in the items regarding the level of consciousness in the NIHSS (1a)~* CT or conventional MRI evidence of brain tumor, cerebral edema with a clinically significant mass midline shift with compression of the ventricles, brainstem or cerebellar infarction, subarachnoid and/or intracerebral and/or intraventricular hemorrhage~* History of ventricular dysrhythmias, acute myocardial infarction within 72 hours prior to enrolment, unstable angina, decompensated congestive heart failure or any other acute, severe, uncontrollable or sustained cardiovascular condition that, in the Investigator's opinion, may interfere with effective participation in the study~* Previous disorders that may confound the interpretation of the neurological scales~* Drug addiction-related disorders~* Pre existing dementia, when dementia implies a disability, measured as an score of 2 or higher in the previous MRS~* Pre existing medical condition that, in the Investigator's opinion, may interfere with the patient's suitability and participation in the study~* Patients participating in another clinical trial or receiving a non-approved drug (clinical investigational drug) less than 30 days prior to screening~* Patients under current treatment with citicoline

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active (Type: EXPERIMENTAL): Receives active drug
- Placebo (Type: PLACEBO_COMPARATOR): Receives a placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Systemic or Perineural Dexamethasone on the Duration of Interscalene Nerve Blocks With Ropivacaine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients undergoing shoulder procedures such as~* Rotator cuff repair~* Capsular shift~* Shoulder arthroplasty~* Subacromial decompression~  • Exclusion Criteria:~ * Contraindications to interscalene block~* Coagulopathy~* Infection at the needle insertion site~* Moderate to severe chronic obstructive pulmonary disease (COPD)~* Contralateral pneumothorax or diaphragmatic paralysis~  * Pregnancy~ * Preexisting neuropathy involving the surgical limb~ * Systemic glucocorticoid treatment (for at least one week) within six months of surgery~ * Routine opioid use (greater than 30 mg oxycodone per day or equivalent)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Ropivacaine with perineural dexamethasone (Type: PLACEBO_COMPARATOR): 30 ml 0.5% ropivacaine plus dexamethasone 8 mg (2 ml) mixed with the local anesthetic with 2 ml normal saline given intravenously (systemic placebo);
- Ropivacaine with systemic steroid (Type: ACTIVE_COMPARATOR): 30 ml 0.5% ropivacaine for interscalene block mixed with 2 ml normal saline (perineural placebo) plus dexamethasone 8 mg (2 ml) administered systemically.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Mechanisms of Allergen Immunotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female~* Age 18 with no upper age limit~* History of seasonal rhino-conjunctivitis in the appropriate season, not controlled by optimised standard medical therapy~* Positive skin prick test to grass pollen or tree pollen~Exclusion Criteria:~* Inadequately controlled or moderate to severe asthma (GINA III/IV), i.e. the FEV1 is below 70 % of the target value despite adequate pharmacotherapy~* Irreversible changes in the reaction organ (emphysema, bronchiectasis, etc.)~* Clinically significant cardiovascular insufficiency (in cardiovascular diseases, there is an elevated risk of adverse reactions to adrenaline)~* Local or systemic use of beta blockers~* Diseases of the immune system (autoimmune diseases, immune complex-induced immunopathies, immunodeficiencies etc.)~* Malignant disease within the past five years (Patients with previous malignant disease that is considered cured may be included subject to the consent of their oncologist)~* Inability to attend regularly for injections and follow-up visits~* Severe atopic dermatitis~* Pregnant or not using adequate contraception (post-menopausal, surgically sterilised, long-term abstinent, or barrier methods plus spermicide)~* Breast-feeding~* Evidence of current drug or alcohol misuse~* Hypersensitivity to any of the SIT (immunotherapy product) excipients~* Active tuberculosis~* Severe mental disorders~* Multiple sclerosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Immunotherapy (Type: OTHER): Open label study of changes to cellular responses following immunotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval